RVTY (Revvity) Current Accrued Expense : $470 Mil (As of Mar. 2025)

View and export this data going back to 1983. Start your Free Trial

What is Revvity Current Accrued Expense?

Revvity's Current Accrued Expense for the quarter that ended in Mar. 2025 was $470 Mil.

Revvity's quarterly Current Accrued Expense declined from Sep. 2024 ($510 Mil) to Dec. 2024 ($203 Mil) but then increased from Dec. 2024 ($203 Mil) to Mar. 2025 ($470 Mil).

Revvity's annual Current Accrued Expense declined from Dec. 2022 ($264 Mil) to Dec. 2023 ($225 Mil) and declined from Dec. 2023 ($225 Mil) to Dec. 2024 ($203 Mil).

Revvity Current Accrued Expense Historical Data

The historical data trend for Revvity's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Current Accrued Expense Chart

Revvity Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

362.48

371.25

263.51

224.57

203.02

Revvity Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															479.25	503.73	510.49	203.02	469.86

Revvity Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Revvity Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Revvity's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Revvity Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

0KHE:UK PKN:Germany PKN:Germany R1VT34:Brazil

Address

77 4th Avenue, Waltham, MA, USA, 02451

Website

https://www.revvity.com

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Executives

Michelle Mcmurry-heath	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Joel S Goldberg	officer: See Remarks	940 WINTER STREET, WALTHAM MA 02451
Tajinder Vohra	officer: Please See Remarks	940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Alexis P Michas	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Anita Gonzales	officer: Please See Remarks	940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
James M Mock	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett	director	C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Pascale Witz	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121